Fourth time's the charm? bluebird picks up new finance chief; New CEOs here and there
→ bluebird bio has been able to cinch two FDA OKs, one for Zynteglo and the other for Skysona, in quick succession, but has had trouble holding onto a CFO. In steps Chris Krawtschuk, who’ll pick up where Jason Cole left off as he hit the exit. Krawtschuk’s been CFO at Jubilant Pharma and MorphoSys and was VP, lead divisional controller at Pfizer. Krawtschuk marks the company’s third CFO just this year — after Cole took over for Gina Consylman, who left for Vedere Bio II — and is left to help steer the company as it begins sales of its nearly $3 million gene therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.